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Abstract 
Background: The chemoresistance of prostate cancer (PCa) is invariably associated with the aggressiveness and 
metastasis of this disease. New emerging evidence indicates that the epithelial-to-mesenchymal transition (EMT) may 
play pivotal roles in the development of chemoresistance and metastasis. As a hallmark of EMT, E-cadherin is sug-
gested to be a key marker in the development of chemoresistance. However, the molecular mechanisms underlying 
PCa chemoresistance remain unclear. The current study aimed to explore the association between EMT and chemore-
sistance in PCa as well as whether changing the expression of E-cadherin would affect PCa chemoresistance.
Methods: Parental PC3 and DU145 cells and their chemoresistant PC3-TxR and DU145-TxR cells were analyzed. PC3-
TxR and DU145-TxR cells were transfected with E-cadherin-expressing lentivirus to overexpress E-cadherin; PC3 and 
DU145 cells were transfected with small interfering RNA to silence E-cadherin. Changes of EMT phenotype-related 
markers and signaling pathways were assessed by Western blotting and quantitative real-time polymerase chain 
reaction. Tumor cell migration, invasion, and colony formation were then evaluated by wound healing, transwell, and 
colony formation assays, respectively. The drug sensitivity was evaluated using MTS assay.
Results: Chemoresistant PC3-TxR and DU145-TxR cells exhibited an invasive and metastatic phenotype that associ-
ated with EMT, including the down-regulation of E-cadherin and up-regulation of Vimentin, Snail, and N-cadherin, 
comparing with that of parental PC3 and DU145 cells. When E-cadherin was overexpressed in PC3-TxR and DU145-
TxR cells, the expression of Vimentin and Claudin-1 was down-regulated, and tumor cell migration and invasion were 
inhibited. In particular, the sensitivity to paclitaxel was reactivated in E-cadherin-overexpressing PC3-TxR and DU145-
TxR cells. When E-cadherin expression was silenced in parental PC3 and DU145 cells, the expression of Vimentin and 
Snail was up-regulated, and, particularly, the sensitivity to paclitaxel was decreased. Interestingly, Notch-1 expression 
was up-regulated in PC3-TxR and DU145-TxR cells, whereas the E-cadherin expression was down-regulated in these 
cells comparing with their parental cells. The use of γ-secretase inhibitor, a Notch signaling pathway inhibitor, signifi-
cantly increased the sensitivity of chemoresistant cells to paclitaxel.
Conclusion: The down-regulation of E-cadherin enhances PCa chemoresistance via Notch signaling, and inhibiting 
the Notch signaling pathway may reverse PCa chemoresistance.
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Background
Prostate cancer (PCa) is the most common cancer and 
the second leading cause of cancer-related deaths in 
men in western countries [1, 2]. In 2014, approximately 
233,000 new cases of PCa were diagnosed and an esti-
mated 29,480 deaths occurred in the United States [2]. 
The incidence of PCa in China is increasing as the lifes-
pan has dramatically increased in the Chinese popula-
tion over the last several decades [3]. Although more 
than 50% of PCa cases initially respond to androgen-
deprivation therapy, most progress to castration-resist-
ant PCa at advanced stages and then become incurable 
[4–6]. Chemotherapy is a major clinical treatment for 
castration-resistant PCa. However, multidrug resistance 
remains a key challenge for the success of chemotherapy 
[7, 8]. Chemoresistant metastatic PCa is the most lethal 
form of cancer in adult men [9]. Thus, effective and alter-
native treatments of PCa are required.
Various steps are involved in cancer progression, 
including the epithelial-to-mesenchymal transition 
(EMT). However, whether EMT plays a role in the chem-
oresistance of PCa remains unclear. EMT is character-
ized by the down-regulation of E-cadherin, an epithelial 
marker; the up-regulation of mesenchymal markers, such 
as Vimentin, N-cadherin, and Snail; and the potently 
enhanced ability of tumor cell invasion and metastasis 
[10–13]. The expression of E-cadherin is used to moni-
tor the epithelial phenotype; loss of E-cadherin expres-
sion is considered a hallmark of EMT, and reduced 
E-cadherin expression occurs during the progression of 
PCa such as migration, invasion, and finally metastasis 
[14–16]. Recent evidence indicated that EMT not only 
causes increased invasion and metastasis but also asso-
ciates with chemoresistance in PCa [17–19]. E-cadherin 
was suggested to be a key marker in the development of 
chemoresistance [20, 21]. However, it has not yet been 
experimentally confirmed whether E-cadherin dominates 
the process of acquiring chemoresistance.
EMT is triggered by the tightly regulated inter-
play between signaling pathways, such as the interplay 
between the Wnt/β-catenin and Akt pathways [22, 23]. 
Recently, Notch signaling was identified to play a sig-
nificant role in EMT in different cancers [24, 25]. Notch 
promotes EMT by regulating several transcriptional and 
growth factors, including transforming growth factor-β 
(TGF-β), Snail, and Slug [26–28]. The Notch signaling 
pathway may also play an important role in cancer chem-
oresistance. For example, the activity of Notch-1 in tumor 
tissues is associated with the resistance to tamoxifen in 
breast cancer patients [29]. In addition, chemotherapy-
induced Notch-1 activation is linked to the acquired 
chemoresistant phenotype of colon cancer cells [30]. Yet, 
whether the Notch pathway is associated with E-cadherin 
in the chemoresistance of PCa remains to be determined.
In the current study, we aimed to explore whether 
EMT, especially the epithelial marker E-cadherin, plays a 
role in the chemoresistance of PCa and tried to identify 
new therapeutic targets. We first determined the mor-
phology and functional characteristics of chemoresistant 
PCa cells. Subsequently, we regulated the expression of 
E-cadherin to investigate the roles of E-cadherin and its 




Human prostate cancer cell lines PC3 and DU145 were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA). They were maintained in RPMI-
1640 supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin and streptomycin (Invitrogen, Carlsbad, 
CA, USA). The paclitaxel-resistant cell lines PC3-TxR 
and DU145-TxR were kind gifts provided by Professor 
Atsushi Mizokami (Kanazawa University, Kanazawa, 
Japan) and were maintained in 10  nmol/L paclitaxel-
contained RPMI-1640 medium. Cell morphology was 
obsevered under an inverted microscope (Olympus, 
Tokyo, Japan) at 200× magnification. Paclitaxel was pur-
chased from Invitrogen. Antibodies against E-cadherin, 
Vimentin, Snail, β-catenin, Claudin-1, Notch-1, Notch-
2, Notch-4, Akt, glycogen synthase kinase-3β (GSK-3β), 
phosphorylated GSK-3β (p-GSK-3β), and nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NF-
κB) p65 were purchased from Cell Signaling Technology 
(Beverly, MA, USA) and β-actin was from Sigma (St. 
Louis, MO, USA). Human E-cadherin-specific small 
interfering RNAs (siRNAs), control siRNA, and lentivi-
ral E-cadherin and control vectors were purchased from 
Genepharma (Shanghai, China). The luciferase reporter 
lentiviral vector and luciferase-expressing cells were con-
structed in our own laboratory. The γ-secretase inhibitor 
(GSI, a Notch inhibitor) was purchased from Calbiochem 
(San Diego, CA, USA).
Animal experiments
Five- to 6-week-old, male severe combined immune defi-
ciency (SCID) mice were purchased from Beijing HFK 
Bioscience (Beijing, China). The animal experiment pro-
tocol was approved by the Institutional Animal Care 
and Use Committee, Guangxi Medical University. All 
mice were housed under specific pathogen-free condi-
tions in accordance with National Institutes of Health 
(NIH) guidelines. Ten mice per group were used. PC3-
luc and PC3-TxR-luc cells (4 ×  106 cells/mouse, mixed 
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with Matrigel [Invitrogen]) were injected subcutaneously 
as indicated, respectively. Tumor growth was monitored 
weekly using a bioluminescence imaging system (Bruker, 
Billerica, MA, USA). Tumor size was measured once a 
week, and tumor volume was calculated using the follow-
ing formula: volume = length × width2 × 0.52 [31]. Mice 
were euthanized by neck dislocation when the tumor vol-
ume was approximately 1 cm3, and tumors were excised 
and photographed.
Semi‑quantitative reverse transcription‑polymerase chain 
reaction (RT‑PCR) and quantitative real‑time PCR
Total RNA was extracted from PC3, DU145, PC3-TxR, 
and DU145-TxR cells using Trizol reagent (Invitro-
gen) according to the manufacturer’s protocol. Two 
micrograms of total RNA were used in each reverse 
transcription. The mRNA expression of E-cadherin, 
Snail, N-cadherin, Vimentin, E-box binding home-
obox-1(ZEB-1), Twist, Smad3, β-catenin, Notch-1, and 
transforming growth factor-β (TGF-β) was detected. 
The primers for semi-quantative RT-PCR and quantita-
tive real-time PCR (qPCR) are listed in Table  1. qPCR 
was performed using a SYBR green assay system on an 
ABI 7300 machine (Applied Biosystems, Waltham, MA, 
USA) as described previously [32]. Triplicate reactions 
were performed for each cDNA sample. Data of each 
gene were confirmed using biological replicate samples. 
The relative expression of each gene to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was calculated 
using the ΔCT method [33].
Western blotting
Cell lysates were prepared according to standard pro-
cedures [34]. Whole cell lysates (50  μg) were separated 
via 10% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis and transferred to polyvinylidene fluo-
ride membrane for Western blotting. The membranes 
were incubated with primary antibodies against E-cad-
herin, Claudin-1, Vimentin, Snail, β-catenin, Notch-1, 
Notch-2, Notch-4, Akt, GSK-3β, p-GSK-3β, NF-κB p65, 
and β-actin overnight at 4  °C. The bands were visual-
ized using a chemiluminescence kit (Thermo Scientific, 
Waltham, MA, USA) after incubation with the corre-
sponding horseradish peroxidase-conjugated second-
ary antibodies (Cell Signaling Technology). β-Actin was 
used as an internal control to confirm the equal loading 
amount of whole cell lysates.
Stable transfection of E‑cadherin
PC3-TxR and DU145-TxR cells (2  ×  105/well) were 
seeded in 12-well plates and cultured overnight at 37 °C. 
The E-cadherin-expressing lentiviral vector and control 
vector were diluted in 0.2 mL (1 × 108 transducing units/
mL) complete medium containing 5  μg/mL polybrene 
(Sigma) and added to cells for a 24-h incubation at 37 °C. 
After the complete medium was replaced, cells were 
incubated for another 48  h. Then, the culture medium 
was changed to complete medium containing puromycin 
(5  µg/mL, Invitrogen), which was replaced every 2  days 
for approximately 2  weeks until all the non-transfected 
cells had died. The expression of E-cadherin gene and 
protein was evaluated using qPCR and Western blotting, 
respectively.
Small interfering RNA transfection
To knockdown E-cadherin expression, PC3 and DU145 
cells were transfected with E-cadherin-specific or control 
siRNA. PC3 and DU145 cells (4 × 105/well) were plated 
in 6-well plates and then transfected with 20  nmol/L 
siRNA using Lipofectamine 2000 (Invitrogen) and 
Table 1 Primers for  semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and  quantitative real-
time PCR
ZEB-1 E-box binding homeobox-1, TGF-β transforming growth factor beta, GAPDH glyceraldehyde-3-phosphate dehydrogenase, bp base pair
Name Forward sequence Reverse sequence Product length (bp)
E-cadherin 5′-CGGGAATGCAGTTGAGGATC-3′ 5′-AGGATGGTGTAAGCGATGGC-3′ 201
Snail 5′-GAAAGGCCTTCAACTGCAAA-3′ 5′-TGACATCTGAGTGGGTCTGG-3′ 249
N-cadherin 5′-AGCCTGGAACATATGTGATGA-3′ 5′-CCATAAAACGTCATGGCAGTAA-3′ 325
Vimentin 5′-GACAATGCGTCTCTGGCACGTCTT-3′ 5′-TCCTCCGCCTCCTGCAGGTTCTT-3′ 236
ZEB-1 5′-TTCAAACCCATAGTGGTTGCT-3′ 5′-TGGGAGATACCAAACCAACTG-3′ 151
Twist 5′-GGAGTCCGCAGTCTTACGAG-3′ 5′-TCTGGAGGACCTGGTAGAGG-3′ 201
Smad3 5′-ACCAGGGCTTTGAGGCTGTC-3′ 5′-GCAAAGGCCCATTCAGGTG-3′ 144
TGF-β 5′-AGGGCTACCATGCCAACTTC-3′ 5′-CCACGTAGTAGACGATGGGC-3′ 168
β-Catenin 5′-GCTGCACAGGTGACCACATT-3′ 5′-GAGTGCTGAAGGTGCTGTCTGT-3′ 238
Notch-1 5′-GGCACTTTCTGTGAGGAGGA-3′ 5′-GCAGTCAGGCGTGTTGTTCT-3′ 147
GAPDH 5′-AGCCACATCGCTCAGACA-3′ 5′-GCCCAATACGACCAAATCC-3′ 66
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cultured for 48  h. Then, total RNA and protein were 
extracted. The expression of E-cadherin gene and pro-
tein was evaluated using qPCR and Western blotting, 
respectively.
Colony formation assay
Cells were seeded in 6-well plates at a density of 400 
cells/well, cultured for approximately 10  days, washed 
with 1×  PBS, fixed with 4% formaldehyde for 15  min, 
and stained using crystal violet (Beyotime, Shanghai, 
China) for 15  min. The colony containing 50 or more 
cells was counted. Three independent experiments were 
performed.
Transwell assay
The cell migration and invasion potentials were evaluated 
using transwell assay [32]. In the migration assays, tumor 
cells (1 ×  105) were seeded into the upper chamber in 
RPMI-1640 medium without FBS. The lower chamber 
contained RPMI-1640 containing 10% FBS. In the inva-
sion assays, growth factor-reduced (GFR) Matrigel inva-
sion chambers (Becton–Dickinson, Franklin Lakes, NJ, 
USA) were used, and cells were seeded into the upper 
chamber of the transwell insert. After incubation for 
24 h, the non-migrating or non-invading cells were gently 
removed using a cotton swab. The remaining cells were 
then fixed with 4% formaldehyde for 5 min, stained with 
crystal violet for 10 min, and counted in five fields under 
an inverted microscope. The independent experiments 
were repeated three times.
Wound healing assay
Wound healing assays were used to evaluate cell migra-
tion. The cells (1  ×  106/well) were seeded in 6-well plates. 
After the cells formed a confluent monolayer, scratches 
were made using a 200-μL pipette tip. The cells were then 
washed with 1×  PBS to remove floating cells, and the 
wound closure was observed at indicated time points and 
photographed under a microscope. All the results were 
analyzed using the ImageJ software (National Institutes 
of Health, Bethesda, Maryland, USA). Wound repair (%) 
was calculated as following: Wound repair = [(Diameter 
of the wound before migration—Diameter of the wound 
after migration)/Diameter of the wound before migra-
tion] × 100%. The mean value of wound repair in three 
duplicate wells was calculated for each group.
MTS assay
Cell survival was measured using a Cell  Titer96® Aque-
ous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA) in the light of the manufactur-
er’s instruction. Briefly, cells were seeded in a 96-well 
plate (2000 cells/well) and incubated with paclitaxel for 
indicated time, then 20 μL MTS solution was added to 
each well and incubated with cells at 37  °C for another 
2  h, at last the absorbance (A490) of each well was read 
at 490 nm. Cells without paclitaxel treatment were used 
as controls. The survival rate was calculated: Survival 
rate =  (A490 of test cells/A490 of control cells) ×  100%. 
The 50% inhibitory concentrations  (IC50) were calculated.
ONCOMINE database analysis of E‑cadherin expression
The expression of E-cadherin in PCa tissues was assessed 
by performing a meta-analysis of the ONCOMINE data-
base, a cancer gene microarray database. Multiple com-
parisons among different studies were analyzed on the 
basis of ONCOMINE algorithms to explain the differ-
ences in their results, similar to a meta-analysis, as previ-
ously described [35].
Statistical analysis
Descriptive statistics including mean values and standard 
error of the mean (SEM) were calculated using Microsoft 
Excel and Prism software (GraphPad, Droitwich, Worces-
tershire, UK). All data were from at least three independent 
experiments; and one-way analysis of variance (ANOVA) 
and Student’s t tests were used to analyze the data.
Results
Chemoresistant PCa cells exhibited EMT morphologic 
changes and expressed EMT‑associated markers
We first observed the morphologic changes in PC3-TxR 
and DU145-TxR cells compared with their parental PC3 
and DU145 cells, respectively. PC3-TxR and DU145-
TxR cells exhibited a spindle-shaped morphology and 
were dispersed, whereas PC3 and DU145 cells were 
round and assembled (Fig.  1a). Semi-quantitative RT-
PCR, qPCR, and Western blotting results showed that, 
in PC3-TxR and DU145-TxR cells, the mRNA and pro-
tein levels of the epithelial marker E-cadherin were sig-
nificantly reduced, whereas the levels of mesenchymal 
markers including Vimentin, Snail, and N-cadherin were 
increased compared with those in PC3 and DU145 cells, 
respectively (Fig. 1b–d).
Chemoresistant PCa cells exhibited enhanced migratory 
and invasive abilities
Transwell assay results showed that the migratory and 
invasive abilities of PC3-TxR and DU145-TxR cells were 
significantly increased compared with PC3 and DU145 
cells, respectively (Fig.  2a, b). Wound healing assay 
results showed that the migration of DU145-TxR cells 
was enhanced significantly compared with that of DU145 
cells (Fig. 2c). The migratory ability of PC3-TxR cells was 
similarly enhanced as that of DU145-TxR cells (data not 
shown).
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Fig. 1 Chemoresistant prostate cancer (PCa) cells show epithelial-to-mesenchymal transition (EMT) changes comparing with their parental 
cells. a Morphology of parental PC3 and DU145 cells, and chemoresistant PC3-TxR and DU145-TxR cells was observed under a microscope at 
200× magnification. b The expression of EMT markers in PC3, DU145, PC3-TxR, and DU145-TxR cells was detected using semi-quantitative reverse 
transcription-polymerase chain reaction (RT-PCR). ZEB-1, E-box binding homeobox-1; TGF-β, transforming growth factor beta; GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase. c Quantitative real-time PCR (qPCR) analysis results show alterations in the mRNA levels of EMT markers in 
chemoresistant cells comparing with parental cells. d The expression of EMT-related proteins in PC3, DU145, PC3-TxR, and DU145-TxR cells was 
analyzed using Western blotting assay. Quantification data are presented as mean ± standard error of the mean (SEM). **P < 0.01, *P < 0.05
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Chemoresistant PCa cells grew faster than parental PCa 
cells in a xenograft mouse model
To assess the tumorigenesis of chemoresistant and paren-
tal PCa cells in vivo, PC3-TxR and PC3 cells that express 
luciferase, named PC3-TxR-luc and PC3-luc cells, 
respectively, were injected subcutaneously into SCID 
mice; tumor growth was monitored. As shown in Fig. 3a, 
the photon intensities in PC3-TxR-luc cell-implanted 
mice were significantly higher than those in the PC3-luc 
cell-implanted mice. The tumor growth curves and final 
tumor sizes showed that PC3-TxR-luc tumors grew faster 
than PC3-luc tumors in mice (Fig. 3b, c).
E‑cadherin overexpression inhibited PC3‑TxR 
and DU145‑TxR cell migration and invasion and partly 
restored paclitaxel sensitivity
Since E-cadherin expression was decreased in chem-
oresistant cells, PC3-TxR and DU145-TxR cells were 
transfected with E-cadherin-specific or control lentiviral 
vectors. After selection, the cells stably overexpressing 
E-cadherin, named PC3-TxR-E-cadherin and DU145-
TxR-E-cadherin cells, were obtained; the control cells 
were named PC3-TxR-control and DU145-TxR-control. 
PC3-TxR-E-cadherin cells became round and assem-
bled compared with PC3-TxR-control cells (Fig.  4a). 
The transfection efficiency was measured using qPCR 
(Fig. 4b) and Western blotting (Fig. 4b), which confirmed 
the high expression of E-cadherin in PC3-TxR-E-cad-
herin cells. Western blotting results for EMT markers 
showed that the expression of Vimentin and Claudin-1 
was decreased in PC3-TxR-E-cadherin cells (Fig.  4c). 
Transwell assay results showed that the overexpression 
of E-cadherin was significantly associated with inhib-
ited migration (Fig. 4d) and invasion (Fig. 4d). Results of 
DU145-TxR cells are similar to those of PC3-TxR cells.
To study the role of E-cadherin in the chemoresistance 
of PC3-TxR and DU145-TxR cells, the survival rates of 
chemoresistant, control, and E-cadherin-overexpressing 
PCa cells treated with different concentrations of pacli-
taxel were assessed using MTS assay. The results showed 
that survival rate was decreased in E-cadherin-overex-
pressing cells compared with those of control and parental 
cells (Fig. 4e). The  IC50 at 72 h was 146.81 ± 1.46 nmol/L 
for PC3-TxR cells, 139.13 ±  4.60  nmol/L for PC3-TxR-
control cells, and 96.20 ± 15.03 nmol/L for PC3-TxR-E-
cadherin cells; 3831.95 ±  65.69  nmol/L for DU145-TxR 
cells, 3725.45  ±  87.36  nmol/L for DU145-TxR-control 
cells, and 3022.10  ±  34.01  nmol/L for DU145-TxR-E-
cadherin cells. Together, these observations suggest that 
overexpression of E-cadherin plays an important role in 
Fig. 2 Chemoresistant PCa cells show enhanced migration and invasion abilities in vitro. a Migratory abilities of PC3, DU145, PC3-TxR, and DU145-
TxR cells were determined using transwell assay. b Invasive abilities were determined using transwell assay. On each filter, five microscopic fields (at 
200× magnification) were observed, and cells were counted. c Migratory abilities of DU145 and DU145-TxR cells were determined using wound 
healing assay. Wounded monolayers of DU145 and DU145-TxR cells were photographed 0, 12, and 24 h after the mechanical scratch, and the widths 
of the wounds were measured in 3-independent wound sites per group. Wound repair was calculated. The mean ± SEM values of data from three 
independent experiments are presented. *P < 0.05, **P < 0.01
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inhibiting migration and invasion and partially restores 
paclitaxel sensitivity of chemoresistant PCa cells.
Silencing E‑cadherin expression caused EMT‑mediated 
paclitaxel resistance in parental PCa cells
To further assess the role of E-cadherin in the chem-
oresistance of PCa cells, two different E-cadherin siR-
NAs were used to silence E-cadherin expression in 
PC3 and DU145 cells (si-E-cadherin-1, target sequence 
2370–2389; si-E-cadherin-2, target sequence 800–818). 
The effective silencing of E-cadhering was confirmed 
by qPCR (Fig.  5a) and Western blotting (Fig.  5a). The 
expression of EMT markers such as Vimentin, Snail, and 
N-cadherin was up-regulated in PC3-si-E-cadherin-1 
and DU145-si-E-cadherin-1 cells (Fig. 5b). Wound heal-
ing assay results showed that the migration of DU145-si-
E-cadherin-1 cells was increased compared with that of 
control cells (Fig.  5c). Colony formation assays demon-
strated that silencing E-cadherin in PC3 and DU145 cells 
inhibited colony formation (Fig.  5d). MTS assay results 
showed that cell survival rate was increased in E-cad-
herin-silencing cells compared with those of control 
and parental cells when treated with paclitaxel (Fig. 5e), 
with  IC50 at 72 h being 9.49 ± 0.89 nmol/L for PC3 cells, 
9.71 ± 2.38 nmol/L for PC3-nc cells, 14.73 ± 1.58 nmol/L 
for PC3-si-E-cadherin-1 cells, 8.31  ±  1.24  nmol/L for 
Fig. 3 Chemoresistant PCa cells demonstrate enhanced subcutaneous tumor growth in mice. a Luminescence imaging of tumors in mice. PC3 
and PC3-TxR cells were transfected with luciferase lentivial vector to construct PC3-luc and PC3-TxR-luc cells, respectively. PC3-luc and PC3-TxR-luc 
cells (4 × 106 cells/mouse) were injected subcutaneously into the right back of male severe combined immune deficiency (SCID) mice, respectively; 
live images on days 14 and 28 are shown. b Tumor growth curves of PC3-luc and PC3-TxR-luc cell xenografts. Tumor volumes were recorded once 
a week. The mean ± SEM values of data from 10 mice per group are presented. c The photo of subcutaneous tumors excised from mice when the 
tumor volume was approximately 1 cm3. *P < 0.05, **P < 0.01
(See figure on next page.) 
Fig. 4 Overexpressing E-cadherin inhibits PC3-TxR and DU145-TxR cell migration and invasion and partly restores paclitaxel sensitivity. a PC3-TxR-
E-cadherin and DU145-TxR-E-cadherin cells show epithelial morphology. Cells transfected with control lentiviral vectors are named PC3-TxR-control 
and DU145-TxR-control, respectively; and cells transfected with E-cadherin-expressing lentiviral vectors are named PC3-TxR-E-cadherin and DU145-
TxR-E-cadherin, respectively. Cell morphology was observed under a microscope at 200× magnification. b qPCR and Western blotting analysis of 
E-cadherin expression. c Western blotting analysis of β-catenin, Vimentin, and Claudin-1 expression. d Migratory and invasive abilities were analyzed 
using transwell assays, and representative photomicrographs of migrating and invading cells were quantified, respectively. e E-cadherin overex-
pression partly reverses paclitaxel resistance in chemoresistant PCa cells. All cells were treated with paclitaxel for 72 h. Cell survival was determined 
using MTS assay. The mean ± SEM values of data from three independent experiments are presented. *P < 0.05, **P < 0.01
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DU145 cells, 8.77 ± 2.40 nmol/L for DU145-nc cells, and 
17.03  ±  1.54  nmol/L for DU145-si-E-cadherin-1 cells. 
The sensitivity to paclitaxel was decreased in E-cadherin-
silenced PCa cells.
Inhibiting the Notch pathway reversed the resistance 
to paclitaxel
To explore whether the Notch signaling pathway is 
involved in EMT-mediated chemoresistance, Notch 
protein levels of parental, chemoresistant, E-cadherin-
overexpressing cells, and their vector control cells were 
measured. Western blotting results confirmed that the 
expression of Notch-1 was up-regulated in PC3-TxR 
and DU145-TxR cells and down-regulated in PC3-TxR-
E-cadherin and DU145-TxR-E-cadherin cells (Fig.  6a). 
Similar results were observed using qPCR (Fig. 6b). Fur-
thermore, Notch-1 levels were up-regulated in PC3-si-
E-cadherin-1 and DU145-si-E-cadherin-1 cells (Fig.  6c). 
Next, PC3-TxR and DU145-TxR cells were treated with 
GSI, a Notch inhibitor, for 72  h, which inhibited the 
expression of Notch-1 and Notch-4 in both cell lines 
(Fig. 6d). GSI (20 µmol/L) alone did not affect the prolif-
eration of PC3-TxR and DU145-TxR cells (Fig. 6e). How-
ever, GSI treatment significantly restored the sensitivity 
of chemoresistant cells to paclitaxel (Fig.  6f ). The 72-h 
 IC50 of paclitaxel for cells treated with GSI and pacli-
taxel was 13.90  ±  1.59  nmol/L for PC3-TxR cells and 
838.00 ± 134.40 nmol/L for DU145-TxR cells, which was 
reduced by 90.5% and 78.8% compared with that for PC3-
TxR and DU145-TxR cells treated with paclitaxel alone, 
respectively.
E‑cadherin expression significantly decreased in PCa 
clinical tissues
Finally, we detected E-cadherin mRNA expression in 
clinical tissue specimens by analyzing gene expression 
datasets in the ONCOMINE database. The data of E-cad-
herin expression in 69 prostate tumor tissues (inclcuding 
38 pT2 cases and 31 pT3-4 cases) and 18 peritumorous 
normal prostate tissues detected using Affymetrix HG-
U133A 2.0 microarrays [35] were collected. The results 
showed that E-cadherin expression was significantly 
decreased in PCa tissues compared with that in peritu-
morous normal tissues (Fig. 7).
Discussion
The resistance to taxanes (paclitaxel or docetaxel) may 
account for tumor relapse and progression, which results 
in skeletal metastasis and high mortality [36]. Neverthe-
less, it is undefined how PCa progresses and specifically 
how chemoresistance occurs. In this study, we observed 
that the morphologic and functional characteristics dif-
fered in chemoresistant and parental PCa cells. EMT-
associated markers were also evaluated, and results 
showed that the expression of E-cadherin was down-reg-
ulated and the expression of Vimentin, Snail, and N-cad-
herin was up-regulated in chemoresistant cells compared 
with parental PCa cells. Enhanced migration and inva-
sion were also observed in chemoresistant cells using 
transwell assays. In addition, chemoresistant cells grew 
faster in male SCID mice than their parental PCa cells. 
Together, these observations strongly suggest that EMT 
is closely associated with chemoresistance in PCa cells.
E-cadherin is a classical cell–cell junction protein that 
is considered a hallmark of EMT [37–39]. In the cur-
rent study, the overexpression of E-cadherin in chem-
oresistant PCa cells resulted in the down-regulation of 
Vimentin and Claudin-1 and inhibited cell migration 
and invasion. Next, the results of sensitivity to paclitaxel 
demonstrated that the overexpression of E-cadherin may 
reverse the chemoresistance in PCa. Meanwhile, silenc-
ing E-cadherin expression in parental cells increased cell 
migration, inhibited colony formation, and enhanced 
paclitaxel resistance of PCa cells. Together with the data 
of E-cadherin expression from the ONCOMINE data-
base, all the results indicated that down-regulation of 
E-cadherin expression might play a fundamental role in 
PCa chemoresistance and metastasis.
To further understand the mechanism behind EMT-
mediated chemoresistance, EMT-related signaling path-
ways involving Akt, GSK-3β, Notch, and NF-κB [37–39] 
were tested. The Notch signaling pathway was identified to 
be altered in the current study. The up-regulation of com-
ponents of the Notch pathway has been observed in clinical 
(See figure on previous page.) 
Fig. 5 Silencing E-cadherin expression in PC3 and DU145 cells causes EMT-mediated paclitaxel tolerance. a qPCR (top) and Western blotting analy-
sis (bottom) of E-cadherin mRNA and protein expression in PC3 and DU145 cell lines after small interfering RNA (siRNA)-mediated E-cadherin silenc-
ing. Cells transfected with negative control siRNA are named PC3-nc and DU145-nc, respectively; cells transfected with E-cadherin siRNA are named 
PC3-si-E-cadherin-1, PC3-si-E-cadherin-2, DU145-si-E-cadherin-1, and DU145-si-E-cadherin-2. b Expression of mesenchymal markers Snail, Vimentin, 
and N-cadherin were measured using qPCR. c Wounded DU145, DU145-nc, and DU145-si-E-cadherin-1 cell monolayers were photographed 0, 24, 
and 36 h after the mechanical scratch, and the width of the wounds was measured in 3 independent wound sites per group. d Colony forma-
tion abilities of parental cells, negative control cells, and E-cadherin-silencing cells were tested. The numbers of colonies are shown. e Silencing 
E-cadherin expression induces the resistance of PCa cells to paclitaxel. Cells were treated with paclitaxel (range: 0–80 nmol/L) for 72 h. Cell survival 
was determined using MTS assay. The mean ± SEM values of data from three independent experiments are presented. **P < 0.01, *P < 0.05
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Fig. 6 Gamma-secretase inhibitor (GSI) significantly increases the sensitivity of chemoresistant cells to paclitaxel. a Western blotting analysis of the 
expression of Notch-1, Akt, glycogen synthase kinase-3β (GSK-3β), phosphorylated GSK-3β (p-GSK-3β), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) p65, and β-actin in parental, chemoresistant, control vector-transfected, and E-cadherin-overexpressing PCa cells. b qPCR 
analysis of Notch-1 expression in the above mentioned cells. c qPCR analysis of Notch-1 expression in E-cadherin-silenced PCa cells. d Notch-1 
expression is inhibited by GSI. Cells were treated with GSI (0, 5, 10, 20 µmol/L) for 72 h. The protein levels of Notch-1, Notch-2, and Notch-4 were 
assayed using Western blotting. e GSI does not inhibit the proliferation of PC3-TxR and DU145-TxR cells. Cells were treated with GSI (20 μmol/L), and 
cell survival was determined using MTS assay. f GSI reverses chemoresistance of PCa cells to paclitaxel. PC3-TxR and DU145-TxR cells were incubated 
with or without 20 µmol/L GSI in the presence of paclitaxel for 72 h. Cell survival was determined using MTS assay. The mean ± SEM values of data 
from 3 independent experiments are presented. *P < 0.05, **P < 0.01
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Fig. 7 E-cadherin mRNA expression level decreases in PCa tumors in 
the meta-analysis of the ONCOMINE database. a E-cadherin mRNA 
expression level is lower in PCa tissues than in peritumorous normal 
prostate tissues. b E-cadherin mRNA expression is significantly lower 
in pT2 and pT3-4 PCa tumors than in peritumorous normal prostate 
tissues. The P value was calculated by Student’s t test, **P < 0.01, 
*P < 0.05
samples of PCa [40], suggesting that the Notch pathway 
may play a crucial role in PCa progression. A correla-
tion between E-cadherin and Notch-1 has been reported 
in trophoblast cells [38] and pancreatic cancer cells [41]. 
However, the relationship between the Notch signaling 
pathway and E-cadherin-mediated chemoresistance in 
PCa is unclear. In the current study, changes of Notch-1 
expression were shown to be opposite to that of E-cadherin 
expression in both chemoresistant and parental PCa cells. 
An important characteristic of the Notch pathway is that 
all ligands and receptors are type I membrane proteins 
[42]. After cell-to-cell interactions, γ-secretase proteolyti-
cally cleaves Notch receptors to release a smaller transcrip-
tional transactivator of Notch, Notch intracellular domain 
(NICD), which translocates into the nucleus to modulate 
the expression of down-stream genes [43]. Therefore, we 
tested the effect of GSI on PCa cells. The results showed 
that GSI inhibited the expression of Notch-1 and Notch-4 
in chemoresistant PCa cells. Further studies showed that 
GSI could remarkably increase the sensitivity of chem-
oresistant cells to paclitaxel. These results suggest that 
down-regulation of E-cadherin contributes to PCa chem-
oresistance via the Notch signaling pathway.
Conclusions
The current study demonstrated that down-regulation of 
E-cadherin contributes to EMT-mediated chemoresist-
ance of PCa. E-cadherin could be a key and “driver” of 
the EMT morphologic changes, and its regulation might 
dictate PCa cell migration and invasion in  vitro as well 
as tumor growth in vivo. Importantly, modulating Notch 
signaling appears to be important since the Notch inhibi-
tor GSI significantly increased the sensitivity of PCa cells 
to paclitaxel. Further pre-clinical testing of this combina-
tion therapy may provide a promising novel strategy for 
PCa treatment.
Abbreviations
PCa: prostate cancer; EMT: epithelial-to-mesenchymal transition; siRNA: small 
interfering RNA; SCID: severe combined immune deficiency; GSK-3β: glycogen 
synthase kinase 3 beta; NF-κB: nuclear factor kappa-light-chain-enhancer 
of activated B cells; NICD: Notch intracellular domain; ZEB-1: E-box binding 
homeobox-1; TGF-β: transforming growth factor beta; GAPDH: glyceralde-
hyde-3-phosphate dehydrogenase.
Authors’ contributions
JZ, YL, JLD, ETK and WCW designed the study and conducted data analysis; 
WCW, LHW conducted data analysis; WCW performed related assays; JZ, LY 
and WCW wrote the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Center for Translational Medicine, Guangxi Medical University, 12th Floor, 
Medical Science Research Building, No. 22 Shuangyong Road, Nanning, 
Guangxi 530021, P. R. China. 2 Key Laboratory of Longevity and Ageing-
related Diseases, Ministry of Education, Nanning, Guangxi 530021, P. R. China. 
3 Department of Urology and Pathology, School of Medicine, University 
of Michigan, Ann Arbor, MI 48109, USA. 4 Department of Urology, Graduate 
School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan. 
5 Department of Biology and School of Medicine, Southern University of Sci-
ence and Technology, Shenzhen, Guangdong 518055, P. R. China. 6 Depart-
ment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 
15232, USA. 
Acknowledgements
We thank Accdon for its linguistic assistance during the preparation of this 
manuscript.
This work was supported by National Natural Science Foundation of China 
(NSFC) Key Project (No. 81130046) and NSFC (Nos. 81272415 and 81171993); 
Guangxi Key Projects (No. 2013GXNSFEA053004); and Youth Science Founda-
tion of Guangxi Medical University (No. GXMUYSF201539).
Competing interests
The authors declare that they have no competing interests.
Received: 24 November 2016   Accepted: 23 March 2017
References
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 
2013;63(1):11–30. doi:10.3322/caac.21166.
 2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 
2014;64(1):9–29. doi:10.3322/caac.21208.
 3. Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortali-
ties of major cancers in China, 2011. Chin J Cancer. 2015;34(11):502–7. 
doi:10.1186/s40880-015-0042-6.
 4. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Ran-
domized comparative study of 3 versus 8-month neoadjuvant hormonal 
therapy before radical prostatectomy: biochemical and pathological 
effects. J Urol. 2001;166(2):500–6.
 5. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, et al. 
Antioxidant therapy alleviates oxidative stress by androgen depriva-
tion and prevents conversion from androgen dependent to castration 
resistant prostate cancer. J Urol. 2012;187(2):707–14. doi:10.1016/j.
juro.2011.09.147.
Page 13 of 13Wang et al. Chin J Cancer  (2017) 36:35 
 6. Gaztanaga M, Crook J. Androgen deprivation therapy: minimizing 
exposure and mitigating side effects. J Natl Compr Cancer Netw. 
2012;10(9):1088–95.
 7. Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, et al. 
ALK and crizotinib: after the honeymoon…what else? Resistance 
mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 
2014;3(4):250–61. doi:10.3978/j.issn.2218-6751.2014.03.01.
 8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman 
MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 
2006;5(3):219–34. doi:10.1038/nrd1984.
 9. Yang Y, Ma Y, Sheng J, Huang Y, Zhao Y, Fang W, et al. A multicenter, 
retrospective epidemiologic survey of the clinical features and manage-
ment of bone metastatic disease in China. Chin J Cancer. 2016;35:40. 
doi:10.1186/s40880-016-0102-6.
 10. Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J 
Dermatol Sci. 2011;61(1):7–13. doi:10.1016/j.jdermsci.2010.11.015.
 11. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells 
A, et al. ZEB1 represses E-cadherin and induces an EMT by recruit-
ing the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 
2010;29(24):3490–500. doi:10.1038/onc.2010.102.
 12. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC. Protein kinase D1 sup-
presses epithelial-to-mesenchymal transition through phosphoryla-
tion of snail. Cancer Res. 2010;70(20):7810–9. doi:10.1158/0008-5472.
can-09-4481.
 13. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, 
et al. Metastatic progression of prostate cancer and e-cadherin regula-
tion by zeb1 and SRC family kinases. Am J Pathol. 2011;179(1):400–10. 
doi:10.1016/j.ajpath.2011.03.028.
 14. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol 
DL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are 
associated with the loss of E-cadherin and an epithelial-mesenchymal 
transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer. 
2005;12(3):631–43. doi:10.1677/erc.1.00958.
 15. Bougen NM, Amiry N, Yuan Y, Kong XJ, Pandey V, Vidal LJ, et al. Trefoil fac-
tor 1 suppression of E-CADHERIN enhances prostate carcinoma cell inva-
siveness and metastasis. Cancer Lett. 2013;332(1):19–29. doi:10.1016/j.
canlet.2012.12.012.
 16. Fan L, Wang H, Xia X, Rao Y, Ma X, Ma D, et al. Loss of E-cadherin 
promotes prostate cancer metastasis via upregulation of metastasis-
associated gene 1 expression. Oncol Lett. 2012;4(6):1225–33. doi:10.3892/
ol.2012.934.
 17. Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol 
Pharm. 2014;11(8):2539–52. doi:10.1021/mp500099g.
 18. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, 
Pereira MV, et al. Epithelial-to-mesenchymal transition mediates doc-
etaxel resistance and high risk of relapse in prostate cancer. Mol Cancer 
Ther. 2014;13(5):1270–84. doi:10.1158/1535-7163.mct-13-0775.
 19. Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, 
et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 
2015;14(1):193–201. doi:10.1158/1535-7163.mct-14-0155.
 20. Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H, et al. Epithelial-to-
mesenchymal transition leads to docetaxel resistance in prostate cancer 
and is mediated by reduced expression of miR-200c and miR-205. Am J 
Pathol. 2012;181(6):2188–201. doi:10.1016/j.ajpath.2012.08.011.
 21. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhe-
sion molecule (EpCAM) is associated with prostate cancer metastasis and 
chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J 
Biochem Cell Biol. 2013;45(12):2736–48. doi:10.1016/j.biocel.2013.09.008.
 22. Zhao JH, Luo Y, Jiang YG, He DL, Wu CT. Knockdown of beta-Catenin 
through shRNA cause a reversal of EMT and metastatic phenotypes 
induced by HIF-1alpha. Cancer Invest. 2011;29(6):377–82. doi:10.3109/073
57907.2010.512595.
 23. Liu J, Chen Y, Shuai S, Ding D, Li R, Luo R. TRPM8 promotes aggres-
siveness of breast cancer cells by regulating EMT via activating AKT/
GSK-3beta pathway. Tumour Biol. 2014;35(9):8969–77. doi:10.1007/
s13277-014-2077-8.
 24. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of 
epithelial-mesenchymal transition phenotype of gemcitabine-resistant 
pancreatic cancer cells is linked with activation of the notch signal-
ing pathway. Cancer Res. 2009;69(6):2400–7. doi:10.1158/0008-5472.
can-08-4312.
 25. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, et al. 
Notch activation results in phenotypic and functional changes 
consistent with endothelial-to-mesenchymal transformation. Circ Res. 
2004;94(7):910–7. doi:10.1161/01.res.0000124300.76171.c9.
 26. Niimi H, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A. Notch 
signaling is necessary for epithelial growth arrest by TGF-beta. J Cell Biol. 
2007;176(5):695–707. doi:10.1083/jcb.200612129.
 27. Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Hofler H. 
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells 
Tissues Organs. 2007;185(1–3):204–12. doi:10.1159/000101321.
 28. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a 
direct Notch target required for initiation of cardiac cushion cellulariza-
tion. J Cell Biol. 2008;182(2):315–25. doi:10.1083/jcb.200710067.
 29. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton 
A, et al. Systematic identification of signaling pathways with potential 
to confer anticancer drug resistance. Sci Signal. 2014;7(357):ra121. 
doi:10.1126/scisignal.aaa1877.
 30. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, et al. gamma-
Secretase inhibitors abrogate oxaliplatin-induced activation of the 
Notch-1 signaling pathway in colon cancer cells resulting in enhanced 
chemosensitivity. Cancer Res. 2009;69(2):573–82. doi:10.1158/0008-5472.
can-08-2088.
 31. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in 
the nude mouse. J Surg Oncol. 1986;31(4):229–34.
 32. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemo-
tactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for 
prostate cancer growth and invasion. Prostate. 2006;66(12):1311–8. 
doi:10.1002/pros.20464.
 33. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, et al. CCR2 expression correlates 
with prostate cancer progression. J Cell Biochem. 2007;101(3):676–85. 
doi:10.1002/jcb.21220.
 34. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Keller ET, et al. PTHrP-
induced MCP-1 production by human bone marrow endothelial cells 
and osteoblasts promotes osteoclast differentiation and prostate cancer 
cell proliferation and invasion in vitro. Int J Cancer. 2007;121(4):724–33. 
doi:10.1002/ijc.22704.
 35. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor 
immunobiological differences in prostate cancer between African–
American and European–American men. Cancer Res. 2008;68(3):927–36. 
doi:10.1158/0008-5472.can-07-2608.
 36. Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, et al. 
Circulating tumor cells in a phase 3 study of docetaxel and prednisone 
with or without lenalidomide in metastatic castration-resistant prostate 
cancer. Eur Urol. 2016. doi:10.1016/j.eururo.2016.07.051.
 37. Lu L, Tang D, Wang L, Huang LQ, Jiang GS, Xiao XY, et al. Gambogic acid 
inhibits TNF-alpha-induced invasion of human prostate cancer PC3 
cells in vitro through PI3K/Akt and NF-kappaB signaling pathways. Acta 
Pharmacol Sin. 2012;33(4):531–41. doi:10.1038/aps.2011.180.
 38. Yu Y, Wang L, Tang W, Zhang D, Shang T. RNA interference-mediated 
knockdown of Notch-1 inhibits migration and invasion, down-regulates 
matrix metalloproteinases and suppresses NF-kappaB signaling pathway 
in trophoblast cells. Acta Histochem. 2014;116(5):911–9. doi:10.1016/j.
acthis.2014.03.003.
 39. Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, et al. Altered 
expression of adhesion molecules and epithelial-mesenchymal transition 
in silica-induced rat lung carcinogenesis. Lab Invest. 2004;84(8):999–1012. 
doi:10.1038/labinvest.3700129.
 40. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch 
expression during murine prostate development and tumorigenesis. 
Cancer Res. 2001;61(19):7291–7.
 41. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithe-
lial-mesenchymal transition consistent with cancer stem cell phenotype 
in pancreatic cancer cells. Cancer Lett. 2011;307(1):26–36. doi:10.1016/j.
canlet.2011.03.012.
 42. Vauclair S, Nicolas M, Barrandon Y, Radtke F. Notch1 is essential 
for postnatal hair follicle development and homeostasis. Dev Biol. 
2005;284(1):184–93. doi:10.1016/j.ydbio.2005.05.018.
 43. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling–
are we there yet? Nat Rev Drug Discov. 2014;13(5):357–78. doi:10.1038/
nrd4252.
